Was the Carmen Bozic Vertex (VRTX) share sale under a 10b5-1 plan?

Yes. The filing states the transaction was made under Dr. Bozic’s company-approved Rule 10b5-1 trading plan. That plan was entered into on November 20, 2025, indicating the sale’s timing was pre-arranged rather than opportunistic.

Vertex (VRTX) CMO Bozic sells 4,062 shares under trading plan

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Vertex Pharmaceuticals EVP and CMO Carmen Bozic reported an open-market sale of common stock. On June 15, 2026, she sold 4,062 shares of Vertex common stock at $450.00 per share. After this transaction, she directly holds 16,953 shares.

The sale was executed under a pre-arranged Rule 10b5-1 trading plan approved by the company and entered into on November 20, 2025. This indicates the timing of the sale was set in advance as part of a structured trading program.

Insider Trade Summary 10b5-1

Net Seller: 4,062 shares ($1,827,900)

Net Sell 1 txn

Insider Bozic Carmen

Role EVP and CMO

Sold 4,062 shs ($1.83M)

Type	Security	Shares	Price	Value
Sale	Common Stock	4,062	$450.00	$1.83M

Holdings After Transaction: Common Stock — 16,953 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Shares sold: 4,062 shares Sale price: $450.00 per share Shares held after transaction: 16,953 shares +2 more

5 metrics

Shares sold 4,062 shares Open-market sale of common stock on June 15, 2026

Sale price $450.00 per share Price for the 4,062 Vertex common shares sold

Shares held after transaction 16,953 shares Direct holdings of Carmen Bozic following the sale

Transaction date June 15, 2026 Date of the reported open-market sale

10b5-1 plan date November 20, 2025 Date Dr. Bozic’s Rule 10b5-1 trading plan was entered into

Key Terms

Rule 10b5-1 trading plan, open-market sale, Common Stock, Executive Vice President and Chief Medical Officer

4 terms

Rule 10b5-1 trading plan regulatory

"Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action: open-market sale of 4,062 shares of common stock"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

"security_title: Common Stock for the reported transaction"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Executive Vice President and Chief Medical Officer financial

"officer_title: EVP and CMO identified for Carmen Bozic"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/17/2026 - 04:12 PM Accepted by SEC EDGAR 06/17/2026 - 04:12 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bozic Carmen

(Last)

(First)

(Middle)

C/O VERTEX PHARMACEUTICALS INCORPORATED

50 NORTHERN AVENUE

(Street)

BOSTON

MASSACHUSETTS

02210

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP and CMO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/15/2026		S⁽¹⁾		4,062	D	$450	16,953	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1, which was entered into on 11/20/2025.

Remarks:

	/s/ Christiana Stevenson, Attorney-in-Fact	06/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Vertex (VRTX) report for Carmen Bozic?

Vertex reported that EVP and CMO Carmen Bozic sold 4,062 shares of common stock. The sale was an open-market transaction at $450.00 per share, and she retained 16,953 shares directly afterward.

At what price did Carmen Bozic sell Vertex (VRTX) shares?

Carmen Bozic sold her Vertex common stock at $450.00 per share. The transaction involved 4,062 shares in an open-market sale and was conducted under a pre-arranged Rule 10b5-1 trading plan.

How many Vertex (VRTX) shares does Carmen Bozic hold after the sale?

After the reported transaction, Carmen Bozic directly holds 16,953 shares of Vertex common stock. This follows her open-market sale of 4,062 shares executed at $450.00 per share on June 15, 2026.

What role does Carmen Bozic hold at Vertex (VRTX)?

Carmen Bozic serves as Executive Vice President and Chief Medical Officer at Vertex. The Form 4 identifies her as an officer, not a director or ten percent owner, and reports her recent open-market sale of Vertex common stock.